Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H3Z7

UPID:
ABHGB_HUMAN

ALTERNATIVE NAMES:
Alpha/beta hydrolase domain-containing protein 16B

ALTERNATIVE UPACC:
Q9H3Z7

BACKGROUND:
The Alpha/beta hydrolase domain-containing protein 16B, or Protein ABHD16B, is distinguished by its unique enzymatic capabilities, contributing to various biochemical processes. The exploration of ABHD16B's structure and function is a vibrant area of scientific inquiry, aiming to elucidate its role in human physiology.

THERAPEUTIC SIGNIFICANCE:
Investigating Protein ABHD16B's biological roles offers a pathway to innovative therapeutic approaches. As research progresses, the potential to harness ABHD16B for clinical applications becomes increasingly feasible, highlighting its importance in advancing medical science.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.